Top

Thrombopoietin receptor agonists post HSCT in pediatric patients

Study number:

Type of transplant:

Diseases:

Short title:

Study status:

Deadline for data collection:

Study design:

Primary objective:

The primary endpoints are: Platelet count on day +30 and +90 after treatment initiation and +30 after treatment discontinuation
Secondary endpoints are: Reduction of platelet transfusions, Possible adverse events, Relapse of primary condition, Status 1 year post HSCT.

Key inclusion criteria:

- Any patient who received Romiplostim or Eltrombopag post HSCT for thrombocytopenia
- Age at HSCT < 18 years
- Diagnosis after 2013
- Allogeneic and/or autologous stem cell transplantation

Country:

Principal investigator:

Asaf David Yanir

Principal investigator email:

EBMT Study coordinator:

Arnaud Dalissier

Need help?

First Name

Last Name

Email address

CIC number

Area of interest

Message box

I understand and accept that my personal data will be used for communication concerning the submitted query or request.

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org